Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects
Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is a multicentre, 2-part, single-blind, randomised, withdrawal, placebo-controlled
study, that includes a 4-week patiromer treatment phase (Part A) followed by an 8-week
randomised placebo-controlled withdrawal phase (Part B) and a 2-week follow-up period.